Lynx1 Capital Management LP - Stock Holdings in 13F Filings (SEC)
Updated on March 15, 2026.
Based on 13F Filings filed with the SEC on February 17, 2026, for the 2025 Q4 period, Lynx1 Capital Management LP held in its portfolio 22 assets valued at $494,001,987 (i.e. $494.00M).
The most valuable assets in the portfolio included: STOKE THERAPEUTICS INC ($171.54M), GH RESEARCH PLC ($132.16M), and CULLINAN THERAPEUTICS INC ($92.77M).
The chart below shows the top 10 valuable assets, and the table below shows the top 22 valuable assets.
You can see similar for other investment managers.
Related Topics: SEC Topic List.
Data Source: SEC.
Lynx1 Capital Management LP - Stock Holdings in 13F Filings (SEC)
Items per page:
25
0 of 0
| Name of Issuer | No. of Shares | Value ($) | Class |
|---|---|---|---|
| STOKE THERAPEUTICS INC | 5404674 | 171544353 | COM |
| GH RESEARCH PLC | 10406575 | 132163502 | ORDINARY SHARES |
| CULLINAN THERAPEUTICS INC | 8963500 | 92772225 | COM |
| DENALI THERAPEUTICS INC | 1738750 | 28706762 | COM |
| C4 THERAPEUTICS INC | 7098133 | 13557434 | COM STK |
| XENCOR INC | 705558 | 10802093 | COM |
| IMMATICS N.V | 921950 | 9680475 | SHS |
| TSCAN THERAPEUTICS INC | 8019148 | 8019148 | COM |
| PASSAGE BIO INC | 623704 | 7359707 | COM NEW |
| KORRO BIO INC | 677915 | 5430099 | COM |
| PRECISION BIOSCIENCES INC | 993913 | 4134678 | COM NEW |
| NEUPHORIA THERAPEUTICS INC | 875228 | 3395885 | COM |
| AGIOS PHARMACEUTICALS INC | 79624 | 2167365 | COM |
| CG ONCOLOGY INC | 31591 | 1311658 | COM |
| ARROWHEAD PHARMACEUTICALS IN | 12043 | 799535 | COM |
| DESIGN THERAPEUTICS INC | 69516 | 652060 | COM |
| ENTRADA THERAPEUTICS INC | 51689 | 531363 | COM |
| WEREWOLF THERAPEUTICS INC | 655926 | 415529 | COM |
| MAPLIGHT THERAPEUTICS INC | 13477 | 236724 | COM |
| GENERATION BIO CO | 25000 | 142000 | COM NEW |
| PROQR THRAPEUTICS N V | 68486 | 138342 | SHS EURO |
| APPLIED THERAPEUTICS INC | 410500 | 41050 | COM |
Popular Topics:
Find us
Copyright © Beautify Data LLC. All Rights Reserved.